Market Cap | 297.80M | P/E | - | EPS this Y | 49.70% | Ern Qtrly Grth | - |
Income | -614.55M | Forward P/E | -1.68 | EPS next Y | 9.00% | 50D Avg Chg | -18.00% |
Sales | 268.22M | PEG | 0.00 | EPS past 5Y | - | 200D Avg Chg | -43.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 30.00% | 52W High Chg | -83.00% |
Recommedations | 3.00 | Quick Ratio | 0.22 | Shares Outstanding | 369.39M | 52W Low Chg | 47.00% |
Insider Own | 5.86% | ROA | -46.40% | Shares Float | 260.52M | Beta | 1.19 |
Inst Own | 54.12% | ROE | - | Shares Shorted/Prior | 64.20M/57.80M | Price | 0.81 |
Gross Margin | -37.86% | Profit Margin | -229.12% | Avg. Volume | 4,619,864 | Target Price | 1.00 |
Oper. Margin | -218.38% | Earnings Date | Nov 6 | Volume | 5,616,310 | Change | -1.86% |
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Kieftenbeld Hermanus | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jun 02 | Sell | 0.95 | 20,999 | 19,949 | 219,768 | 06/02/23 |
ALVAREZ EDUARDO | CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER | Apr 04 | Sell | 1.23 | 231,368 | 284,583 | 612,546 | 04/06/23 |
Kung Frank | Director Director | Sep 20 | Sell | 3.55 | 600,000 | 2,130,000 | 09/22/22 | |
Kung Frank | Director Director | Sep 15 | Sell | 3.87 | 3,298,776 | 12,766,263 | 109,460 | 09/19/22 |
KELSEY NICOLE | CHIEF LEGAL OFFICER-.. CHIEF LEGAL OFFICER- SECRETARY | Sep 02 | Sell | 2.87 | 5,019 | 14,405 | 58,314 | 09/07/22 |
ALVAREZ EDUARDO | CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER | Sep 02 | Sell | 2.87 | 22,421 | 64,348 | 351,914 | 09/07/22 |
Kieftenbeld Hermanus | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Sep 02 | Sell | 2.87 | 25,888 | 74,299 | 240,767 | 09/07/22 |
Melo John | President and CEO President and CEO | Aug 15 | Buy | 4.03 | 17,155 | 69,135 | 509,856 | 08/17/22 |
Melo John | President and CEO President and CEO | Jul 06 | Sell | 2.15 | 55,576 | 119,488 | 492,701 | 07/08/22 |
Hughes Anthony | CHIEF ACCOUNTING OFF.. CHIEF ACCOUNTING OFFICER | Jun 02 | Sell | 2.3401 | 6,305 | 14,754 | 106,612 | 06/03/22 |
KELSEY NICOLE | CHIEF LEGAL OFFICER-.. CHIEF LEGAL OFFICER- SECRETARY | Jun 02 | Sell | 2.3401 | 8,406 | 19,671 | 157,366 | 06/03/22 |
Kieftenbeld Hermanus | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jun 02 | Sell | 2.34 | 34,905 | 81,678 | 266,655 | 06/03/22 |
Kung Frank | Director Director | Apr 15 | Option | 4.51 | 3,156,446 | 14,235,571 | 938,416 | 04/15/21 |